Literature DB >> 22177802

uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells.

Hari Raghu1, Arun Kumar Nalla, Christopher S Gondi, Meena Gujrati, Dzunh H Dinh, Jasti S Rao.   

Abstract

The uPA/uPAR system is known to play a critical role in angiogenesis of glioblastoma. Previously, we have shown that shRNA against uPA and uPAR attenuates angiogenesis by blocking nuclear translocation of angiogenin, inhibition of angiopoietin/Tie2 signaling, and regulating several other pro-angiogenic, angiostatic and anti-angiogenic molecules. Further analysis revealed that GM-CSF, a pleiotropic cytokine, was significantly inhibited in U87MG and 4910 co-cultures with endothelial cells transfected with shRNA against uPA and uPAR. The role of the uPA/uPAR system in this process is not completely understood. Analysis of tumor conditioned medium of U87MG, 4910 and HMECs transfected with shRNA against uPA or uPAR alone or in combination (pU2) revealed inhibition of GM-CSF-enhanced secretion of SVEGFR1 as shown by Western blotting and ELISA. Moreover, phosphorylation of JAK2 and STAT5, the downstream effectors of GM-CSF signaling, was also inhibited in all three cell lines. Phosphorylation at Tyr 166 position of the GM-CSFRβ subunit, the signal activating subunit of the GM-CSF receptor, was inhibited in HMEC, U87MG and 4910 cells. Further analysis revealed that shRNA against uPA and/or uPAR increased secretion of TIMP-1, which is known to enhance SVEGFR1 secretion in endothelial cells. Moreover, addition of purified uPA (with and without GM-CSF) activated JAK2/STAT5 signaling in HMEC. Exogenous addition of SVEGFR1 to pU2 tumor conditioned medium enhanced inhibition of VEGF-induced endothelial capillary tube formation as assessed by an in vitro angiogenesis assay. To determine the significance of these events in vivo, nude mice with pre-established tumors treated with shRNA against uPA and/or uPAR showed decreased levels of GM-CSF and increased levels of SVEGFR1 and TIMP-1 when compared with controls. Enhanced secretion of SVEGFR1 by puPA, puPAR and pU2 in endothelial and GBM cells was mediated indirectly by MMP-7 and augmented by ectodomain shedding of VEGFr1 by tyrosine phosphorylation at the 1213 position. Taken together, these results suggest that the uPA/uPAR system could prove beneficial as an indirect target for inhibition of angiogenesis in glioblastoma.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22177802      PMCID: PMC3268919          DOI: 10.1016/j.molonc.2011.11.008

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  57 in total

Review 1.  uPAR: a versatile signalling orchestrator.

Authors:  Francesco Blasi; Peter Carmeliet
Journal:  Nat Rev Mol Cell Biol       Date:  2002-12       Impact factor: 94.444

Review 2.  Effect of antisense inhibition of Urokinase receptor on malignancy.

Authors:  L Ossowski
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

3.  The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells.

Authors:  I Dumler; A Weis; O A Mayboroda; C Maasch; U Jerke; H Haller; D C Gulba
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

Review 4.  Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets.

Authors:  Pia Vihinen; Veli-Matti Kähäri
Journal:  Int J Cancer       Date:  2002-05-10       Impact factor: 7.396

5.  Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.

Authors:  Nader Rahimi; Todd E Golde; Rosana D Meyer
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

6.  Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo.

Authors:  S Mohanam; S W Wang; A Rayford; M Yamamoto; R Sawaya; M Nakajima; L A Liotta; G L Nicolson; W G Stetler-Stevenson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1995-01       Impact factor: 5.150

7.  Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells.

Authors:  Ta-Kashi Ito; Genichiro Ishii; Seiji Saito; Keiichi Yano; Ayuko Hoshino; Tasuku Suzuki; Atsushi Ochiai
Journal:  Blood       Date:  2008-10-30       Impact factor: 22.113

8.  Regulation of soluble vascular endothelial growth factor receptor 1 secretion from human endothelial cells by tissue inhibitor of metalloproteinase 1.

Authors:  E Bruegmann; R Gruemmer; J Neulen; K Motejlek
Journal:  Mol Hum Reprod       Date:  2009-07-07       Impact factor: 4.025

Review 9.  Novel anti-angiogenic therapies for malignant gliomas.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Lancet Neurol       Date:  2008-12       Impact factor: 44.182

10.  Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.

Authors:  Hari Raghu; Sajani S Lakka; Christopher S Gondi; Sanjeeva Mohanam; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

View more
  17 in total

Review 1.  Nanoparticulate RNA delivery systems in cancer.

Authors:  Ankur Sharma; Niraj Kumar Jha; Kajal Dahiya; Vivek Kumar Singh; Kundan Chaurasiya; Aditya Narayan Jha; Saurabh Kumar Jha; Prabhu Chandra Mishra; Sunny Dholpuria; Rani Astya; Parma Nand; Amit Kumar; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-30

2.  uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells.

Authors:  Hari Raghu; Arun Kumar Nalla; Christopher S Gondi; Meena Gujrati; Dzunh H Dinh; Jasti S Rao
Journal:  Mol Oncol       Date:  2011-11-30       Impact factor: 6.603

Review 3.  VEGF-initiated angiogenesis and the uPA/uPAR system.

Authors:  Johannes M Breuss; Pavel Uhrin
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

4.  The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis.

Authors:  Dawei Li; Ping Wei; Zhihai Peng; Chen Huang; Huamei Tang; Zhiliang Jia; Jiujie Cui; Xiangdong Le; Suyun Huang; Keping Xie
Journal:  Clin Cancer Res       Date:  2012-11-07       Impact factor: 12.531

5.  Differential roles of uPAR in peritoneal ovarian carcinomatosis.

Authors:  Nada N Al-Hassan; Ali Behzadian; Ruth Caldwell; Vessela S Ivanova; Viqar Syed; Kouros Motamed; Neveen A Said
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

6.  Identification of Glioblastoma Phosphotyrosine-Containing Proteins with Two-Dimensional Western Blotting and Tandem Mass Spectrometry.

Authors:  Tianyao Guo; Xiaowei Wang; Maoyu Li; Haiyan Yang; Ling Li; Fang Peng; Xianquan Zhan
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

7.  The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model.

Authors:  Eric C Woolf; Kara L Curley; Qingwei Liu; Gregory H Turner; Julie A Charlton; Mark C Preul; Adrienne C Scheck
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

8.  Exosomes of adult human fibroblasts cultured on 3D silk fibroin nonwovens intensely stimulate neoangiogenesis.

Authors:  Peng Hu; Anna Chiarini; Jun Wu; Giuliano Freddi; Kaiyu Nie; Ubaldo Armato; Ilaria Dal Prà
Journal:  Burns Trauma       Date:  2021-05-04

Review 9.  Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.

Authors:  Niaz Mahmood; Catalin Mihalcioiu; Shafaat A Rabbani
Journal:  Front Oncol       Date:  2018-02-12       Impact factor: 6.244

10.  SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma.

Authors:  Romain Bibes; Stéphane Gobron; François Vincent; Carole Mélin; Nicolas Vedrenne; Aurélie Perraud; Francois Labrousse; Marie-Odile Jauberteau; Fabrice Lalloué
Journal:  Oncotarget       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.